New England Journal of Medicine · 2010 · 1.9K citations · 18 references
MedicineOncologyRadiation OncologyBreast OncologyRadiobiologyTreatment PlanningBreast Cancer RadiobiologyBreast Cancer RadiotherapyBreast Radiation CareHypofractionated Breast RadiotherapyRadiation TherapyRegional Nodal IrradiationBreast Cancer FractionationHypofractionated Radiation TherapyHypofractionated Whole-breast IrradiationHypofractionation ToxicityLong-term EffectivenessModerate HypofractionationPost-mastectomy Radiotherapy
BACKGROUND: The optimal fractionation schedule for whole-breast irradiation after breast-conserving surgery is unknown. METHODS: We conducted a study to determine whether a hypofractionated 3-week schedule of whole-breast irradiation is as effective as a 5-week schedule. Women with invasive breast cancer who had undergone breast-conserving surgery and in whom resection margins were clear and axillary lymph nodes were negative were randomly assigned to receive whole-breast irradiation either at a standard dose of 50.0 Gy in 25 fractions over a period of 35 days (the control group) or at a dose of 42.5 Gy in 16 fractions over a period of 22 days (the hypofractionated-radiation group). RESULTS: The risk of local recurrence at 10 years was 6.7% among the 612 women assigned to standard irradiation as compared with 6.2% among the 622 women assigned to the hypofractionated regimen (absolute difference, 0.5 percentage points; 95% confidence interval [CI], -2.5 to 3.5). At 10 years, 71.3% of women in the control group as compared with 69.8% of the women in the hypofractionated-radiation group had a good or excellent cosmetic outcome (absolute difference, 1.5 percentage points; 95% CI, -6.9 to 9.8). CONCLUSIONS: Ten years after treatment, accelerated, hypofractionated whole-breast irradiation was not inferior to standard radiation treatment in women who had undergone breast-conserving surgery for invasive breast cancer with clear surgical margins and negative axillary nodes. (ClinicalTrials.gov number, NCT00156052.)
18
Bernard Fisher, Stewart Anderson, John Bryant et al. · New England Journal of Medicine · 2002 · 6.2K citations · Full text
Harry Bartelink, Jean-Claude Horiot, Philip Poortmans et al. · Journal of Clinical Oncology · 2007 · 1K citations